S 8308: inhibits binding of angiotensin II to its receptors; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 196748 |
| CHEBI ID | 79977 |
| MeSH ID | M0164089 |
| Synonym |
|---|
| 119256-78-9 |
| s 8308 |
| cv 2961 |
| 2-butyl-4-chloro-1-(2-nitrobenzyl)imidazole-5-acetic acid |
| 1h-imidazole-5-acetic acid, 2-butyl-4-chloro-1-((2-nitrophenyl)methyl)-, sodium salt |
| s-8308 |
| CHEBI:79977 |
| Q27149142 |
| sodium 2-(2-butyl-4-chloro-1-(2-nitrobenzyl)-1h-imidazol-5-yl)acetate |
| sodium;2-[2-butyl-5-chloro-3-[(2-nitrophenyl)methyl]imidazol-4-yl]acetate |
| 1h-imidazole-5-acetic acid, 2-butyl-4-chloro-1-[(2-nitrophenyl)methyl]-, sodium salt (1:1) |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The higher dose of CV-2961 (100 micrograms/min) completely blocked angiotensin II-induced enhancement of vascular responses to sympathetic nerve stimulation and shifted the angiotensin dose-response curve 10-fold to the right with respect to angiotensin II-induced increases in mesenteric perfusion pressure." | ( Blockade of the pre- and postjunctional effects of angiotensin in vivo with a non-peptide angiotensin receptor antagonist. Inagami, T; Jackson, EK, 1990) | 0.28 |
| Class | Description |
|---|---|
| organic molecular entity | Any molecular entity that contains carbon. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (14.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||